As of July 16, 2025, Mayne Pharma Group Ltd (MYX.AX) reports a Net Margin of -44.06%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Mayne Pharma Group Ltd's Net Margin
Over recent years, Mayne Pharma Group Ltd's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-06-30 | -44.06% |
| 2023-06-30 | 61.61% |
| 2022-06-30 | -178.47% |
| 2021-06-30 | -51.92% |
| 2020-06-30 | -20.27% |
This gradual decrease highlights how Mayne Pharma Group Ltd manages its overall profitability and cost control over time.
Comparing Mayne Pharma Group Ltd's Net Margin to Peers
To better understand Mayne Pharma Group Ltd's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Mayne Pharma Group Ltd (MYX.AX) | -44.06% |
| Consun Pharmaceutical Group Ltd (1681.HK) | 30.68% |
| YungShin Global Holding Corp (3705.TW) | 14.55% |
| Fuji Pharma Co Ltd (4554.T) | 13.33% |
| Vita Life Sciences Ltd (VLS.AX) | 11.05% |
| Jianmin Pharmaceutical Group Co Ltd (600976.SS) | 10.33% |
Compared to its competitors, Mayne Pharma Group Ltd's Net Margin is about average compared to peers, reflecting typical industry profitability.